ICON Public Limited (NASDAQ:ICLR) Shares Purchased by Horizon Investments LLC

Horizon Investments LLC boosted its stake in ICON Public Limited (NASDAQ:ICLR) by 534.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 653 shares of the medical research company’s stock after acquiring an additional 550 shares during the quarter. Horizon Investments LLC’s holdings in ICON Public were worth $137,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. First Horizon Advisors Inc. boosted its stake in shares of ICON Public by 33.9% during the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after buying an additional 151 shares during the last quarter. Icon Wealth Advisors LLC lifted its stake in ICON Public by 861.1% during the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after purchasing an additional 11,840 shares during the last quarter. Foyston Gordon & Payne Inc bought a new position in ICON Public during the third quarter worth $11,672,000. GAMMA Investing LLC increased its position in ICON Public by 64.0% in the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after buying an additional 169 shares during the period. Finally, Steph & Co. increased its position in ICON Public by 3.7% in the fourth quarter. Steph & Co. now owns 1,560 shares of the medical research company’s stock worth $327,000 after buying an additional 55 shares during the period. Hedge funds and other institutional investors own 95.61% of the company’s stock.

ICON Public Price Performance

Shares of ICLR stock opened at $183.96 on Friday. The stock’s fifty day simple moving average is $193.43 and its 200 day simple moving average is $227.86. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.26 and a quick ratio of 1.34. The firm has a market cap of $14.86 billion, a price-to-earnings ratio of 19.30, a P/E/G ratio of 1.86 and a beta of 1.21. ICON Public Limited has a one year low of $174.93 and a one year high of $347.72.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.41 by $0.01. The business had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.04 billion. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. On average, analysts expect that ICON Public Limited will post 13.38 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ICLR. William Blair reaffirmed an “outperform” rating on shares of ICON Public in a report on Tuesday, January 14th. Truist Financial decreased their price objective on ICON Public from $284.00 to $262.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Robert W. Baird decreased their price objective on ICON Public from $221.00 to $203.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Barclays cut their price target on ICON Public from $275.00 to $240.00 and set an “overweight” rating for the company in a research note on Friday, February 21st. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $263.00 price objective on shares of ICON Public in a research note on Wednesday, January 15th. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, ICON Public presently has an average rating of “Moderate Buy” and a consensus target price of $279.17.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.